ストックスクリーナーアプリを入手
153.55
2.27%
2.89
前日終値:
$150.66
開ける：
$151
24時間の取引高:
3.69M
Relative Volume:
0.35
時価総額：
$379.11B
収益：
$65.51B
当期純損益:
$8.93B
株価収益率:
43.21
EPS:
3.5532
ネットキャッシュフロー:
$14.12B
1週間 パフォーマンス:
+13.99%
1か月 パフォーマンス:
+17.56%
6か月 パフォーマンス:
+25.82%
1年 パフォーマンス:
+80.57%
1日の値動き範囲:
$150.66
$155.10
1週間の範囲:
$144.90
$155.10
52週間の値動き範囲:
$77.58
$155.10
Merck Co Inc Stock (MRK) Company Profile
Compare MRK vs LLY, JNJ, ABBV, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
153.66 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,256.65 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
272.55 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
266.13 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
159.52 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-02-13 | アップグレード | Deutsche Bank | Hold → Buy |
| 2026-01-08 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-10-13 | 再開されました | Citigroup | Neutral |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-02-18 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-02-10 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-01-08 | ダウングレード | Truist | Buy → Hold |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-12-04 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-11 | ダウングレード | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-03-11 | ダウングレード | Societe Generale | Hold → Sell |
| 2024-01-04 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-27 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | アップグレード | UBS | Neutral → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Hold |
| 2023-04-13 | アップグレード | Citigroup | Neutral → Buy |
| 2023-03-28 | ダウングレード | Societe Generale | Buy → Hold |
| 2023-03-13 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 開始されました | Jefferies | Buy |
| 2023-02-22 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-10-10 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-14 | アップグレード | Berenberg | Hold → Buy |
| 2022-07-06 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 再開されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-16 | 開始されました | Daiwa Securities | Neutral |
| 2021-12-13 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-12-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-29 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-01 | アップグレード | Argus | Hold → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-20 | ダウングレード | Argus | Buy → Hold |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-08-03 | アップグレード | Goldman | Neutral → Buy |
| 2020-06-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-16 | 開始されました | SVB Leerink | Outperform |
| 2019-07-03 | 開始されました | Mizuho | Buy |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-05-13 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 繰り返されました | Citigroup | Buy |
| 2018-10-09 | 再開されました | Guggenheim | Buy |
| 2018-04-23 | アップグレード | Goldman | Neutral → Buy |
| 2018-04-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-03-12 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-07 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2018-01-16 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Merck Co Inc (MRK) 最新ニュース
The Goldman Sachs Group Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock - MarketBeat
Strong Merck stock trades close to its 52-week high as analysts lift targets after melanoma trial wi - Ad-hoc-news.de
Merck & Co Inc Stock (MRK) Moved Up by 3.41% on Aug 21: Facts Behind the Movement - TradingKey
Moderna and Merck cancer vaccine success paves way for future - EMJ
TCW Group Inc. Sells 16,921 Shares of Merck & Co., Inc. $MRK - MarketBeat
Summit Global Investments Sells 15,559 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Commonwealth Retirement Investments LLC - MarketBeat
Crew Capital Management Ltd Acquires 7,742 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Acumen Wealth Advisors LLC - MarketBeat
RBC Capital Downgrades Merck & Co as Profit-Taking Sets In - marketscreener.com
Merck & Co. stock hits record high as cancer vaccine data lifts 2026 outlook - Ad-hoc-news.de
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $170.00 - MarketBeat
Merck Raises the Stakes for Pfizer's Cancer Vaccine AmbitionsModerna (NASDAQ:MRNA), Merck & Co (NYSE:M - Benzinga
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $175.00 - MarketBeat
Merck & Co. stock extends double-digit August rally as analyst calls and cancer vaccine data reshape - Ad-hoc-news.de
RBC Capital downgrades Merck & Co as profit-taking hits the stock - marketscreener.com
Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades - Seeking Alpha
Merck & Co., Inc. (NYSE:MRK) Downgraded to "Sector Perform" Rating by Royal Bank Of Canada - MarketBeat
This Merck Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Elon Musk Backs mRNA As Moderna's Stock Soars on Cancer Vaccine WinModerna (NASDAQ:MRNA) - Benzinga
Merck & Co., Inc. (NYSE:MRK) Raised to Overweight at Morgan Stanley - MarketBeat
Goldman Sachs Adjusts Price Target on Merck & Co. to $160 From $140, Keeps Buy Rating - Moomoo
Merck & Co., Inc. (NYSE:MRK) Stock Rating Lowered by Jefferies Financial Group - MarketBeat
Morgan Stanley Upgrades Merck & Co. to Overweight From Equalweight, Adjusts PT to $179 From $116 - marketscreener.com
Jennison Associates LLC Has $350.67 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Holdings Trimmed by Hohimer Wealth Management LLC - MarketBeat
Hodges Capital Management Inc. Sells 8,148 Shares of Merck & Co., Inc. $MRK - MarketBeat
Massachusetts Financial Services Co. MA Reduces Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. stock jumps to record high as cancer vaccine data eases Keytruda risk - Ad-hoc-news.de
MERCK & CO INC : JEFFERIES RAISES TARGET PRICE TO $175 FROM $152 - Moomoo
Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today? - TradingView
Healthcare Stocks After Hours: Moderna, Merck Cool Following Cancer Trial GainsPfizer (NYSE:PFE), Mode - Benzinga
Merck & Co Inc : Argus Research Raises Ta - Moomoo
MRNA, BULL, BMNR, MSTR, MRK: 5 Trending Stocks TodayModerna (NASDAQ:MRNA) - Benzinga
Shareholders that lost money on Merck & Co., Inc.(MRK) should con - The National Law Review
Why Moderna Stock Skyrocketed Today - The Motley Fool
Moderna and Merck: Intismeran's Positive Phase 3 Readout Confirms mRNA Potential in Oncology - Morningstar
Moderna or Merck: Which Soaring Cancer Vaccine Stock Is the Better Buy? - Finviz
Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In FocusMerck & Co (NYSE:MRK) - Benzinga
Merck & Co Inc (MRK) Stock Up 12.6% but GF Value Says Overvalued -- GF Score: 72/100 - GuruFocus
Merck's Large Late-Stage Pipeline Is Building Solid Defense Against Keytruda's Patent Cliff - Morningstar
Pfizer Stock Rises Wednesday: What's Going On? - Benzinga
Stock Traders Buy High Volume of Merck & Co., Inc. Call Options (NYSE:MRK) - MarketBeat
Huge Unusual Put Options Volume in MerckIs MRK Stock Overvalued? - Barchart.com
MERCK CO INC - Financial Post
Merck Soars On Cancer Vaccine Trial Win With Moderna, More Upside Ahead (NYSE:MRK) - Seeking Alpha
Merck: Why Consolidation Looks Like The Next Move (Rating Downgrade) (NYSE:MRK) - Seeking Alpha
Merck stock hits a new 52-week high on melanoma data - Ad-hoc-news.de
Moderna's Cancer Vaccine Win Is Merck's Story Too - Benzinga
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition - Benzinga
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results - Reuters
Merck Co Inc (MRK) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
大文字化:
|
ボリューム (24 時間):